Coreline Soft Supplies Lung Cancer Screening AI to Charité - Universitätsmedizin Berlin
Il sito "il Centro Tirreno.it" utilizza cookie tecnici o assimiliati e cookie di profilazione di terze parti in forma aggregata a scopi pubblicitari e per rendere più agevole la navigazione, garantire la fruizione dei servizi, se vuoi saperne di più leggi l'informativa estesa, se decidi di continuare la navigazione consideriamo che accetti il loro uso.
Informativa estesa
14
Dom, Giu

Abbiamo 2900 visitatori e nessun utente online

Coreline Soft Supplies Lung Cancer Screening AI to Charité - Universitätsmedizin Berlin

Immediapress
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

COMUNICATO STAMPA - CONTENUTO PROMOZIONALE

Entering a major German clinical hub as the LCS market shifts from "product adoption" to "standardized infrastructure competition." 

BERLIN, March 23, 2026 /PRNewswire/ -- Coreline Soft, a leading medical AI company, has supplied its lung cancer screening (LCS) AI solution to

Charité – Universitätsmedizin Berlin, Germany's largest university hospital. This marks the company's entry into a core clinical hub for Germany's National Lung Cancer Screening (LDCT-based LCS) system. Charité, ranked 7th globally by Newsweek (2025), is a public institution operated by the federal government and the state of Berlin, serving as a benchmark for national health policies and clinical guidelines.  

Key Highlights of the Implementation 

The Product: AVIEW LCS Plus, optimized for Low-Dose CT (LDCT) lung cancer screening. 

Integrated Analysis: It automatically analyzes lung nodules, COPD (Chronic Obstructive Pulmonary Disease), and CAC (Coronary Artery Calcification) from a single CT scan, enhancing efficiency and reading consistency. 

Proven Reliability: The solution was previously verified through the HANSE project (Germany's national LCS pilot program), demonstrating operational stability in multi-center environments. 

Strategic Shift: From Tools to Infrastructure 

Germany is transitioning from a pilot phase to a formal national LCS system. The Federal Joint Committee (G-BA) plans to implement LDCT-based screening under statutory health insurance benefits within the first half of this year. Consequently, the market is shifting toward standardized processes—including participant screening, double-reading, follow-up, and quality control—rather than simple hospital-by-hospital adoption. 

To meet strict requirements like double-reading protocols and data pseudonymization, Coreline Soft introduced AVIEW HUB, a centralized platform for multi-center screening operations. This platform internalizes quality control functions, ensuring regulatory compliance while reducing the manual workload for medical staff. 

Coreline Soft's Competitive Edge 

Industry experts evaluate that Charité's adoption signals a move from "product performance" to "screening operation infrastructure competition." As the national reimbursement system solidifies standard processes, companies with multi-center operational experience and hub-based management capabilities, like Coreline Soft, are expected to strengthen their long-term global competitiveness. 

Logo - https://mma.prnewswire.com/media/2521520/CorelineSoft_Logo.jpg  

View original content:https://www.prnewswire.co.uk/news-releases/coreline-soft-supplies-lung-cancer-screening-ai-to-charite--universitatsmedizin-berlin-302719633.html  

Copyright 2026 PR Newswire. All Rights Reserved. 

COMUNICATO STAMPA - CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall'ente che lo emette. L'Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

Author: RedWebsite: http://ilcentrotirreno.it/Email: Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.